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Abstract
The LIM homeodomain gene Islet-1 (ISL1) encodes a transcription factor that has been associated with the multipotency of
human cardiac progenitors, and in mice enables the correct deployment of second heart field (SHF) cells to become the
myocardium of atria, right ventricle and outflow tract. Other markers have been identified that characterize subdomains of
the SHF, such as the fibroblast growth factor Fgf10 in its anterior region. While functional evidence of its essential
contribution has been demonstrated in many vertebrate species, SHF expression of Isl1 has been shown in only some
models. We examined the relationship between human ISL1 and FGF10 within the embryonic time window during which
the linear heart tube remodels into four chambers. ISL1 transcription demarcated an anatomical region supporting the
conserved existence of a SHF in humans, and transcription factors of the GATA family were co-expressed therein. In
conjunction, we identified a novel enhancer containing a highly conserved ISL1 consensus binding site within the FGF10
first intron. ChIP and EMSA demonstrated its direct occupation by ISL1. Transcription mediated by ISL1 from this FGF10
intronic element was enhanced by the presence of GATA4 and TBX20 cardiac transcription factors. Finally, transgenic mice
confirmed that endogenous factors bound the human FGF10 intronic enhancer to drive reporter expression in the
developing cardiac outflow tract. These findings highlight the interest of examining developmental regulatory networks
directly in human tissues, when possible, to assess candidate non-coding regions that may be responsible for congenital
malformations.
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Introduction
Congenital heart malformations occur in approximately 3 per
1000 births, more than half of which are potentially lethal
malformations of the outflow tract (OFT) [1]. Extensive studies
have been undertaken to identify factors driving the differentiation
of cell populations that participate in OFT formation in mice and
other species, with the expectation that functional data about
evolutionarily conserved molecules can be extrapolated to human
development.
Two spatially distinct groups of myocardial progenitors, located
in the first and the second heart fields, contribute to the definitive
heart pump [2,3]. The chambers proper are derived from the
former, while the outflow segment of the right ventricle and great
arteries and the inflow portion of the atria come from the latter.
Initially identified in mouse and chick embryos, there appears to
be equivalent spatial segregation between progenitor lineages in
lower vertebrates without four-chambered hearts, recently iden-
tified in frog [4] and fish [5].
Coordination between these separate but adjacent mesodermal
primordia is orchestrated by signaling events that converge on a
common palette of transcription factors necessary for the site-
appropriate differentiation of the multiple cell types present in a
mature heart. The LIM homeodomain transcription factor Islet-1
(Isl1) is one of these. Isl1 is necessary for multipotent cardiovas-
cular progenitors within the second heart field to proliferate,
survive, and migrate into the forming heart. Isl1 is highly
conserved over chordate evolution in this role [4,6]. Isl1-null mice
die at mid-gestation from gross cardiac malformations, notably the
lack of the OFT and right ventricle myocardium [7]. Isl1 is also
known to be critical for formation and specification of motoneu-
rons [8] and of the pancreas [9], acting in combination with other
transcription factors to attain specific and context-dependent
effects on differentiation [8].
In the developing heart, these combinatorial partners include
members of the tinman (Nkx), GATA-binding and T-box (Tbx)
families [10–12], which may derepress and add permissive marks
to chromatin [13]. Such associations indeed appear to be
stabilized by the preparatory activity of Swi/Snf-like BAF
chromatin remodelling complexes expressed precisely within heart
precursor primordia, such as Smarcd3 (Baf60c) [14].
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early mesodermal transcription factors Mef2c and Nkx2-5 during
cardiac development via elements in their promoters that also
contain nearby, active GATA-binding sites [10,15]. In return,
human NKX2-5 itself can bind the GATA4 promoter to positively
control its transcription during fetal cardiomyocyte differentiation
[16], while forced co-expression of Smarcd3, Gata4 and Tbx5 can
induce Isl1 and Nkx2.5 expression in murine mesoderm not
normally fated to integrate the heart, leading to cardiac
transdifferentiation [17].
No ISL1 coding mutations have been identified in humans,
probably because of an embryonic lethal phenotype for complete
inactivation and no gross effect of haploinsufficiency, as seen for
murine Isl1 [7]. Heterozygous ISL1 mutations have not directly
been reported to cause conotruncal cardiopathies either, although
a block of single nucleotide polymorphisms around and within
ISL1 have indeed been found to be in linkage disequilibrium with a
risk for complex congenital heart phenotypes involving ‘‘develop-
mental structures aberrantly formed as derivatives of the
secondary [sic] heart field.’’ [18].
In Isl1 homozygous knockout mice, the residual hearts no
longer express certain bone morphogenetic protein (Bmp) or Wnt
family members, Fgf8 or Fgf10, and are missing the OFT entirely
[7]. Fgf10, a secreted member of the fibroblast growth factor
family, also characterizes the splanchnic mesoderm of the anterior
majority of the murine second heart field [3]. In the mouse, its
genetic ablation leads to absence of pulmonary arteries and veins,
malposition of the heart apex and thin-walled myocardium
[19,20]; the absence of the cognate specific receptor isoform for
Fgf10, Fgfr2-IIIb, leads in knockout mice to pulmonary vessel
aplasia and to OFT malformations such as double outlet right
ventricle or ventricular septal defects with overriding aorta [19].
Despite its strong and specific expression in the murine OFT, the
function of cardiac Fgf10 has been difficult to ascertain, and its
direct transcriptional regulation by Isl1 suggested but not
demonstrated in this tissue. Only Tbx1 and Tbx5 have so far
been shown to directly bind to and positively regulate Fgf10
expression in the OFT through a 59 enhancer element [21,22].
However, Isl1 and Fgf10 also play early roles in the specification
and outgrowth of vertebrate hindlimbs [23–25], while a consensus
Isl1-binding site was identified in silico within a 0.4 kb Fgf10
promoter element that is highly conserved among amniotes and
capable of directing expression to the otic anlage [26].
The phenotype of Fgf10-null mice demonstrates the irreplace-
able role of Fgf10 in epithelial-mesenchymal interactions needed
for the development of many organ systems, including but not
restricted to endodermal organs and glands of the head and neck
[24,27,28]. However, there appears to be partial functional
redundancy with other Fgf family members, including Fgf3 and
Fgf8, in the heart and great vessels [29–31], and different Fgfs in
other organ systems such as the inner ear, pituitary and limb buds
[32,33]. Human heterozygous mutations of FGF10 lead to isolated
or syndromic aplasia of the lacrimal and salivary glands and ducts
[34,35], not clearly involving the heart, hindgut, ear, pancreas or
limbs, that were severely affected in homozygous knockout mice
but less so or not at all in heterozygotes. The effect on the lungs is
subtle and cumulative in haploinsufficient patients, leading to
chronic obstructive pulmonary disease [36]. Like for ISL1,n o
biallelic inactivation of FGF10 has been found to date in human
disease [37], but the more subtle effects of Fgf10
+/2 phenotypes
have only been described progressively over the years since the
first murine knockout models.
The spatiotemporal expression of human ISL1 has recently been
demonstrated to be compatible with the existence of a subset of
embryonic progenitors that would contribute specifically to the
inflow and outflow tracts, as in animal models [11], or that
maintain developmental plasticity at later fetal stages [38]. In this
work, we demonstrate not only that ISL1 is co-expressed with
other transcription factors in the cardiac primordium, but that in
vivo it directly binds and positively regulates the transcription of
FGF10. ISL1 exerts this effect through an enhancer within the
FGF10 first intron that is evolutionarily conserved among
mammals, becomes additionally responsive to ISL1 in vitro in the
presence of GATA and TBX factors, and is capable of responding
to endogenous cardiac OFT transcription factors in a transgenic
mouse reporter.
Results
ISL1 binds a novel intronic element of the FGF10 gene in
the human heart but not hindlimb
Recent results from our and other groups have demonstrated the
expression of both FGF10 and ISL1 in a region probably
corresponding to a second heart field in human embryos at
appropriate and similar stages of morphogenesis [11,37]. A non-
exhaustive bioinformatics analysis of the FGF10 locus to search for
putative highly conserved ISL1 consensus binding sites with the
sequence YTAATGR, using rVista 2.0 (http://rvista.dcode.org)
[39] and the ECR browser (http://ecrbrowser.dcode.org) [40],
identified two candidate regions conserved among therian mam-
mals(Fig.1A). One hadbeenpreviouslypredictedwithintheFGF10
promoter [26] and was also common to birds and amphibians,
which we termed FGF10-Pr2; another, within the first intron of
FGF10, was termed FGF10-Int1. A third promoter region, without
an ISL1 consensus binding site, was designated as FGF10-Pr1. A
non-canonical (i.e. 59-TGATTA-39) potential binding site for
GATA-type transcription factors [41] was observed 52 nucleotides
59 to the ISL1 cognate sequence in FGF10-Int1 and these sites were
nearly identical in nucleotide composition and distance from one
another between mice and humans (Fig. 1B). This attracted our
attention to three additional potential sites for homeobox-
containing transcription factors and another GATA site, as well
as a putative, but less conserved, canonical T-box (Fig. 1C), making
all of FGF10-Int1 a candidate cis-regulatory module [42]. All other
sites identified, within evolutionarily conserved modules, were
100% identical between species.
Using chromatin immunoprecipitation (ChIP) of microdissected
embryonic human hearts, we demonstrated that at Carnegie stages
14–15 (33–36 dpf), ISL1 bound to and enriched a 327 bp FGF10-
Int1 fragment (Fig. 2A). In contrast, ISL1 did not occupy FGF10-
Pr1 or FGF10-Pr2. Acetylated histone H4 did bind both the ISL1
and FGF10 promoters at CS14-15, confirming that the chromatin
around these two promoters is transcriptionally active in the
human heart at these stages (Fig. 2B) [43].
We also examined whether ISL1 could bind to the FGF10-Int1
element in developing human hindlimb buds, since FGF10 and
ISL1 are co-transcribed at foot plate stages at CS16-17 (37–43 dpf;
Fig. 2C). While FGF10-Int1 was occupied by ISL1 in the CS14-15
heart, ChIP performed on CS16-17 hindlimbs demonstrated no
equivalent binding of ISL1 to FGF10-Int1 (Fig. 2D).
ISL1 and GATA4/5/6 are transcribed in the same temporal
window as FGF10
In light of the presence of putative conserved GATA-binding
sites in FGF10-Int1, we examined the expression of potential
cardiac GATA partners and compared it to that of ISL1 at a range
of stages covering the morphogenetic changes from directional S-
shaped looping of the primitive cardiac tube to the appearance of
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extracted from microdissected, staged human heart primordia
demonstrated that ISL1, GATA4, GATA5, GATA6, and FGF10,
were all expressed at CS13-15 (28–36 dpf). In contrast, these genes
were no longer transcribed at CS16 (37–40 dpf), despite continued
expression of the ubiquitous ACTB (Fig. 3 inset).
Figure 1. Bioinformatics analyses of the human FGF10 locus surrounding the first exon. A: Alignment of genomic regions around and
within the human [hg18] FGF10 locus to those of frog [xenTro2], chicken [galGal3], opossum [monDom4], mouse [mm9], dog [canFam2] and rhesus
macaque [rheMac2] with colored regions .90% identical and the vertical scale ranging from 50% (bottom) to 100% (top). Color code for genomic
features at http://ecrbrowser.dcode.org/ecrInstructions/ecrInstructions.html. The FGF10-Pr1, FGF10-Pr2 and FGF10-Int1 regions examined in this
study are boxed. B: A non-canonical predicted site for GATA-type transcription factors is 52 nucleotides 59 to the ISL1 cognate sequence in FGF10-Int1
in the direction of transcription on the – strand in humans, mice and (not shown) macaque and opossum. C: Nucleotide sequence of the FGF10-Int1
enhancer module and position of conserved putative transcription factor binding sites as predicted by rVista (http://rvista.dcode.org). All indicated
human sites are identical to those of the macaque and mouse except for the SMAD prediction, only found in mouse; the ISL1, GATA and HOXA7 sites
are also identical to the opossum, and the ISL1, NKX2-5 and TBX sites are also identical to the dog.
doi:10.1371/journal.pone.0030677.g001
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was observed in the outflow tract region, while ISL1 hybridization
was only visible in the endoderm of the ventral foregut (Fig. 3A). In
agreement with the RT-PCR data, at CS13-15 both ISL1 and
GATA4 were transcribed within the cardiac mesenchyme sur-
rounding the aorticopulmonary trunk (see magnifications Fig. 3F–
H and I–K, respectively). ISL1 also maintained expression at CS15
within the splanchic mesenchyme between the trachea and the
heart, while GATA4 appeared restricted to the endocardium and
myocardium at CS14-15.
ISL1 and GATA4 each can bind the FGF10-Int1 element in
vitro
To investigate the specificity of ISL1 binding to its consensus
site within FGF10-Int1, we performed an electrophoretic mobility
shift assay (EMSA, Fig. 4). ISL1 bound robustly to its FGF10-ISL1
site, as well as to a previously identified positive control site [10],
termed Insulin I-ISL1 (Fig. 4, lanes 2 and 7 respectively). The
FGF10-ISL1 binding was specific, since it could be partially
competed off by excess unlabeled probe (Fig. 4, lane 3) but not by
a hundredfold excess of unlabeled mutated probe (Fig. 4, lane 4).
In addition, ISL1 did not bind to a labeled, scrambled FGF10-
ISL1 sequence (Fig. 4, lane 5).
In order to verify the affinity of the nearby, non-canonical
GATA site in FGF10-Int1 for GATA4, we performed another
EMSA, confirming that GATA4 was able to occupy this sequence
(Fig. 4, lane 12). Binding to the 59-TGATTA-39 site was
completely abrogated by the addition of unlabeled FGF10-GATA4
probe (Fig. 4, lane 13).
ISL1 and GATA4 cooperate with TBX20 to activate FGF10
via its intronic enhancer
The transcriptional response of murine Nkx2.5 to the combina-
tion of Isl1 and Gata4 in vitro can be potentiated by Tbx20, a
member of a large family of genes whose products share a
common DNA-binding domain, similar to the T (brachyury)
transcription factor [15]. We first determined the ability of ISL1
and/or GATA4 to promote luciferase activity using a reporter
with a minimal promoter containing the human cardiac-
responsive FGF10-Int1 fragment located 39 to the luciferase
sequence, mimicking the endogenous location of this regulatory
element relative to the initiation site for FGF10 transcription. Co-
transfection into mesenchymal 10T1/2 cells of a GATA4 or ISL1
expression construct, together with the FGF10-Int1-luciferase
reporter, indeed resulted in robust activation of luciferase activity
(Fig. 5).
We then tested whether this human FGF10-Int1 element could
drive expression of a luciferase reporter gene in the presence of
ISL1, GATA4, and TBX20 proteins separately as well as in
combination. Despite the presence of only a single, non-
palindromic T-box binding core motif [45] within the intronic
response element (Fig. 1), transfection of TBX20 in addition to
GATA4 and ISL1 expression constructs resulted in additive
activation of FGF10-Int1-luc (Fig. 5).
Transgenic mouse embryos express FGF10-Int1-driven
reporter in cardiac OFT
The strict sequence conservation between humans and mice,
and the ability of transfected murine cells to demonstrate ISL1-
and cofactor-driven activation of a reporter gene containing the
FGF10-Int1 enhancer in vitro, led us to then test the ability of the
element to drive reporter expression when introduced in vivo.
FGF10-Int1 was therefore subcloned into the pTK-nlacZ reporter
plasmid [46] and introduced into mouse blastocysts. 43 embryos
out of 66 injected were recovered at E8.5, 22 of 53 at E9.5, 46 of
94 at E10.5, and 37 of 59 at E11.5. Of these, nine animals had
integrated the transgene, confirmed by PCR, and expressed beta-
galactosidase activity: n=2 at E8.5, n=3 at E9.5, n=1 at E10.5
and n=3 at E11.5.
Labelled cells were observed in the cardiac outflow tract in two
of the reporter embryos, at E9.5 and E10.5 respectively,
demonstrating the conserved ability of this enhancer to drive
gene transcription in both mouse and human hearts. Expression in
both cases concerned a few dozen cells, which were not observed
in other heart compartments (Fig. 6A–B). Among the positive
embryos, a restricted set of additional tissues were also labelled,
varying in combinations from one embryo to another in an age-
appropriate manner (Table 1). These included the forebrain, the
lens, the three first pharyngeal arches, the pancreatic primordia
(dorsal and ventral; Fig. 6C), a subset of dorsal root ganglia cells,
and motoneurons (Fig. 6D–E). Scattered cells were also positive in
the rostral presomitic mesoderm in both E8.5 embryos. Although
neither cardiac nor pharyngeal arch expression were visible in the
three E11.5 embryos, the tunica media of the internal carotid
Figure 2. In vivo and in vitro binding of ISL1 and GATA4 within
the first intron of FGF10.A : Results of end-point PCR after ChIP using
anti-ISL1 or non-specific IgG (or no antibody at all) on chromatin
derived from human embryonic hearts at Carnegie stages (CS)14-15. B:
Analogous results using anti-acetylated histone H4 compared to a non-
specific IgG or no antibody at all, and end-point PCR of regions in the 59
promoter to human ISL1 and FGF10, demonstrating active availability
for transcription. C: FGF10 and ISL1 (and ACTB) were co-expressed at
foot plate stages (Carnegie stages [CS]16-17, i.e. 37–43 days of
gestation) in human hindlimbs as seen by RT-PCR, while only FGF10
and ACTB were transcribed in forelimbs. D: ChIP using anti-ISL1 on
chromatin derived from the C16–17 hindlimb demonstrates no
enrichment of the FGF10-Int1 amplicon as compared to the negative
control, although this fragment is amplifiable from the total input
chromatin.
doi:10.1371/journal.pone.0030677.g002
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ganglia were labelled in another. Overall, the sites of transgenic
labelling are compatible with activation by Isl1, given what is
known about its expression pattern in all of these sites at these
stages of development [7,9,47,48], and thus with its positive
regulation of FGF10 transcription in both the human and murine
cardiac OFT.
Discussion
We have found that within the first intron of the FGF10 gene
there exist highly evolutionarily conserved consensus binding sites
for equally conserved transcription factors of the LIM homeodo-
main, GATA and T box families. These sites are arranged in such
a way as to represent a functional cis-regulatory module, with
physical spacing between the binding sites that is itself also
conserved across species, in particular that between the ISL1 and
GATA cognate sites. We have demonstrated that in the human
embryonic heart, this module is physically occupied by ISL1
during the period corresponding to the establishment of the
cardiac chambers but before septation of the OFT [44]. Binding of
ISL1 to the intronic element of FGF10 then ceases in the cardiac
OFT, but is never observed in the human or mouse hindlimb bud,
for example, where both Isl1 and Fgf10 are expressed shortly
thereafter. This observation shows tissue specificity in the function
of this binding site and is consistent with the ISL1 expression
pattern that we and others [11] have observed in the human
embryonic OFT as well as in the splanchnic mesoderm between
CS13-15, as reported in mouse at equivalent morphological stages
[49]. Despite a great deal of study of tissue-specific enhancers
engaged by Isl1 [10,50] and the control of Fgf10 expression by
transcription factors in the limb [51] and inner ear [26,52], this is
the first report of cis-regulation of FGF10 expression through an
intronic element during cardiac development.
In situ hybridization to GATA4 transcripts in adjacent sections
demonstrated that at CS12, unlike the morphologically equivalent
stage in the mouse [53], no GATA4 expression was observed in the
OFT region. Other subtle differences exist as well between the
mouse and human patterns, notably the lack of ISL1 expression
outside of the pharyngeal endoderm at CS12, when in the mouse,
Figure 3. Expression of ISL1 and GATA4 transcripts in the human heart between 26 and 38 days of gestation. A–H: ISL1 in situ at
Carnegie stages (CS)12 (26–28 days post fertilization [dpf]), CS13 (28–31 dpf), CS14 (32–33 dpf) and CS15 (34–36 dpf) respectively. E–H are
magnifications of A–D respectively. I–K show GATA4 expression in adjacent sections to B–D. A: ISL1 is expressed at CS12 in foregut endoderm,
splanchnic mesoderm, and early motoneurons. B, F: At CS13, ISL1 is transcribed by mesenchyme around the cardiac OFT and pharyngeal arches. ISL1
expression continues in the splanchnic mesoderm between the trachea and OFT, and is visible in dorsal root ganglia, at CS14 (C, G) and CS15 (D, H).
I–K: GATA4 is expressed in the endocardium and myocardium of the arterial pole at CS13, CS14 and CS15 (I, J, K respectively). Inset: RT-PCR of ISL1,
GATA4, GATA5, GATA6, FGF10 and positive control ACTB mRNAs in embryonic human hearts at stages CS13-16 (to 40 dpf). Abbreviations: drg, dorsal
root ganglia; es, esophagus; fb, forebrain; fg, foregut; ph, pharynx; nt, neural tube; oft, OFT; ra, right atrium; t, trachea. Arrows, motoneurons. Bar:
110 mm (A–D, I) and 55 mm (E–H, J, K).
doi:10.1371/journal.pone.0030677.g003
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mesoderm from an earlier stage [7]. During murine OFT
maturation, Isl1- and Gata4-expressing cardiac mesenchyme is
also colonized by neural crest cells. However, in the mouse, Isl1 is
never expressed in migrating neural crest cells [7], and Gata4 is
rapidly downregulated in both mesectodermal and cardiac neural
crest cells [54]. The subpopulation of human ISL1-positive cells in
the OFT, that apparently also co-expresses GATA4, is thus likely to
be mesodermal in origin. This localization is compatible with the
regulation of FGF10.
This conclusion is supported by transgenic mice in which the
human FGF10 response element was introduced to drive
transcription of a reporter gene, yielding labeled cells in the
OFT at stages that morphologically precede cardiac chamber
formation. Our complementary in vitro experiments further
demonstrated that the single binding site for ISL1 in the
1047 bp FGF10 response element enriched by ChIP is sufficient
to drive a three-fold increase in luciferase activity in response to
the presence of ISL1 alone. This represents significant and strong
activation, since the reporter construct did not contain tandem
ISL1 recognition sites but rather preserved the in vivo arrangement
of multiple predicted binding sites for conserved transcription
factors. Despite the absence of a palindromic T-box consensus site
within the intronic response element of FGF10, we obtained
transactivation of the reporter, which is in accordance with
previous studies showing the response of murine Nkx2.5 to Tbx20
even in the absence of a cognate T-box element [15]. Together
with the capacity of GATA4 to transactivate the same reporter in
an additive fashion, these results are consistent with a combina-
torial action of transcription factors on FGF10 non-coding
elements to confer a state of either permission or transcriptional
activation to otherwise refractory chromatin.
Among the many dozens of genes highly conserved through
evolution and identified as key effectors of animal cardiogenesis,
only a handful of them, including a disproportional number of
transcription factors (GATA4, NKX2.5, ZIC3, TBX1,TBX20 and
CHD7 [55–60]), but also intracellular effectors (TAB2 [61], MID1
[62]) and ligands (BMP4 [56]) or membrane-bound proteins
(STRA6 [63,64], NOTCH1 [65], and CFC1 [66]), have so far been
directly linked to congenital heart malformations of the OFT in
humans. Mutations in these genes can lead, infrequently and often
in association with other developmental anomalies, to persistent
truncus arteriosus, double outlet right ventricle, interruption or severe
hypoplasia of the aortic arch, tetralogy of Fallot, and valvulo-
Figure 4. Electrophoretic mobility shift assays demonstrate specific binding of both ISL1 and GATA4 to the conserved FGF10
intronic element (FGF10-Int1). Lane 1, 9, 10: WT FGF10-ISL1 site probe alone, or in conjunction with ISL1 (lane 2) and with unlabeled competitor,
which reduces the amount of shifted probe (lane 3), or with ISL1 and unlabeled competitor carrying a mutation in the ISL1 binding site (lane 4).
Mutated ISL1 does not shift this probe (lane 5). Lane 6: A validated tandem set of ISL1 binding sites from the insulin promoter shows no gel shift
unless ISL1 is added (lane 7) and this shift is reduced in the presence of unlabelled probe competitor (lane 8). Lane 11, 14: WT FGF10-GATA site probe
alone, or in conjunction with GATA4 (lane 12) and with unlabeled competitor, which completely abrogates the shift of the probe (lane 13).
doi:10.1371/journal.pone.0030677.g004
Figure 5. In vitro reporter assays support an additive combi-
natorial effect of transcription factors upon the FGF10 intronic
enhancer. LUC-FGF10-Int1, which construct placed the luciferase gene
under the control of the FGF10-Int1 element, was transfected alone or
together with ISL1, GATA4 and TBX20 expression vectors into 10T1/2
cells. Each factor alone potentiated luciferase expression and these
effects were additive in combination.
doi:10.1371/journal.pone.0030677.g005
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murine and human gene inactivation phenotypes, with many
excellent candidate genes through their function in animal model
cardiac development not having been found to be mutated in their
human counterpart coding sequences.
FGF10 is one of these latter genes, whose cardiac knockout
phenotype in the mouse is itself subtle. Based on the murine
phenotypes of Fgf10 and Fgfr2-IIIb knockouts and their expression
patterns [3,19], we had previously found very similar expression
during normal human embryonic development; however, se-
quencing of both FGF10 and FGFR2-IIIb in human fetuses
exhibiting great vessel defects that resembled those in knockout
mice, among other symptoms, did not demonstrate coding
mutations [37]. The responsible gene turned out to encode a
protein, STRA6, necessary to bring vitamin A into cells, a first step
in transcriptional regulation through retinoic acid receptor binding
[63,64]. Retinoic acid, a vitamin A metabolite, normally favors
Gata4 transcription and limits the spatial expansion of Isl1, Fgf8
and Fgf10 expression in the SHF [67–69], while it promotes Fgf10
transcription in the burgeoning lungs [70]. Coding mutations in
FGF10 lead to phenotypic defects only in the submandibular and
lachrymal glands and lungs [34,35], despite being as present as
Stra6 [71] in many other organ systems. Similarly, heterozygous
missense coding mutations in human FGF8 have been shown to be
associated with non-syndromic cleft lip and palate [72], cause
pleiotropic defects in forebrain and pituitary formation [73], and a
recent case of recessive holoprosencephaly with asymptomatic,
consanguineous parents has been attributed to hypomorphic
alleles of FGF8 [74]; none of these patients presented cardiac
malformations. These observations emphasize the danger of
extrapolating findings about the detailed mechanisms of action
of highly conserved genes across species, and demonstrate the
limits of animal models in understanding human organogenesis.
There is increasing evidence that mutations in non-coding, cis-
regulatory elements, controlling transcript availability at a given
point time or a given tissue, represent an alternative mechanism
leading to human congenital malformations. Such mutations can
take the forms of those found for coding sequences, involving
single nucleotides [75] or small or large chromosomal rearrange-
ments [76]. We have discovered an evolutionarily conserved cis-
regulatory module in the FGF10 gene that is functional during
human cardiac development and that could represent an example
of the types of non-coding sites in which mutations may be
responsible for morphological aberrations. Taken together, our
data reveal unexpected complexity in the transcriptional landscape
controlling human cardiogenesis, highlight evolutionary conserva-
tion as well as species-specific aspects of cardiac signalling
networks, and contribute a strategy to identify additional
candidate genomic regions for study in congenital malformations
of the OFT.
Materials and Methods
Ethics statement
Human embryos were obtained from electively terminated
pregnancies, anonymously donated to research after informed
written consent from donors in concordance with French
legislation (94–654 and 08–400) and with prior approval of the
protocol (to M.V.) from the Necker ethical review committee. All
mice used in this study were housed under specific pathogen-free
conditions at the mouse genetics engineering center (C.I.G.M.) of
the Pasteur Institute, Paris, under authorization number A75-15-
09 from the Paris Departmental Directorate for the Protection of
Populations and handled in accordance with French and
European directives.
Chromatin immunoprecipitation
ChIP was carried out as previously described, starting from
nuclear isolation [77], using eleven microdissected and flash-
frozen cardiac tubes from human embryos at Carnegie stages (CS)
14–15 [78]. An anti-ISL1 (10 mL, Santa Cruz Sc-23590X) or an
anti-GFP antibody as negative control (10 mL, Abcam ab1218),
were used per 10 mg of sonicated chromatin. Immunoprecipitated
DNA was analysed by end-point PCR (primers, Supplementary
Table S1).
Figure 6. Transgenic mice demonstrate responsiveness of the
conserved FGF10 intronic enhancer to endogenous transcrip-
tion factors within the developing cardiac OFT and other sites.
A 1047 bp enhancer region within the first intron of human FGF10,
containing multiple transcription factor binding sites including sites
validated for ISL1 and GATA4, was placed ahead of a lacZ reporter gene
under a thymidine kinase-driven promoter. A: Transgenic mouse at
embryonic day (E)10.5, in which expression was activated in dispersed
cells of the posterior outflow tract (magnified, insets), in a distal/lateral
subdomain of the first two pharyngeal arches, in cells within the
trigeminal, acoustic and dorsal root ganglia, and in the lens (right side).
B: Same embryo; frontal view. C: Transgenic mouse at E11.5, dorsal and
ventral pancreatic primordia. No expression was observed in the limb
buds in any injected embryos. In a different transgenic mouse at E11.5,
D: motoneuron columns from inner surface of the lumbar spinal cord,
and E: cross-section of spinal cord with a labelled subpopulation of cells
in the dorsal root ganglia.
doi:10.1371/journal.pone.0030677.g006
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ISL1 and GATA4 in situ hybridizations were performed using
transverse sections of normal human embryos from CS12 to 15.
Tissue fixation, sectioning, and in situ hybridization were carried
out as previously described [79]. Total RNA was extracted from
pooled whole hearts at individual stages from CS13 to CS16 and
RT-PCR was carried out using the GeneAmp kit (Roche), with
500 ng total RNA input for first strand synthesis (primers,
Supplementary Table S1).
Expression constructs and electrophoretic mobility shift
assays (EMSA)
Human TBX20 and ISL1 expression vectors were generated.
Full-length TBX20 cDNA and a fragment of ISL1 cDNA with the
N-terminal 142 amino acids removed [80] were inserted into the
multiple cloning site of pcDNA3.1C (Invitrogen). Full-length
human GATA4 cDNA was purchased from GenScript
(GN026113). HeLa cells were transfected with these constructs,
and nuclear protein extracts were made using standard protocols.
The LightShift Chemiluminescent EMSA Kit (Pierce) was used as
specified. Primers are listed in Supplementary Table S1.
Transactivation assays and reporter constructs
For the FGF10 reporter construct (LUC-FGF10-Int1), 1047 bp
of the FGF10 first intron (NCBI36/hg18 chromosome
5:44421556–44422602) were subcloned into the BamHI site 39
to luc+ in pGL3 (Promega). Mouse 10T1/2 cells [81] in DMEM/
10% fetal calf serum were transfected with FuGene HD (Roche).
Cells were harvested and lysed 24 h after transfection. Firefly and
Renilla luciferase activities were measured on a Berthold Centro
LB960 using the Dual-Luciferase Reporter assay system (Pro-
mega). Firefly luciferase activity was normalized to the Renilla
luciferase internal control, pRL-CMV (Promega). Experiments
were repeated in triplicate in three independent assays.
Transgenesis
The same 1047 bp FGF10-Int1 fragment as in the transactiva-
tion assays was subcloned into the BamHI site of the pSKT-TK-
nLacZ plasmid [46] and orientation verified by capillary
sequencing with a standard T3 primer. The plasmid was
linearized with SalI for injection at 2 ng/mL into mouse
blastocysts. b-galactosidase-containing cells that had transcribed
the reporter plasmid were stained in whole mount by the catalysis
of the X-gal (5-bromo-4-chloro-3-indolyl b-D-galactopyranoside)
substrate.
Supporting Information
Figure S1 Composite image of embryonic hearts at stages
ranging from the beginning of the fourth to the ninth week of
human gestation (upper left to lower right, Carnegie stages 10–23).
Rostral to top. Congenital heart and great vessel malformations
arise during this time window when molecular signaling between
cardiac progenitors and their environment is impaired.
(TIF)
Table S1 Primer sequences for PCR and EMSA.
(DOC)
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